According to a research study by Chinese medical experts, a non-invasive diagnostic product based on urine tumor DNA has been proven to effectively detect urothelial carcinoma (UC) in its early stages. The overall diagnostic sensitivity of the product is reported to be 91.37%, significantly improving the early detection rate of urothelial carcinoma.
The findings of this research, led by Professor Ye Dingwei from the Department of Urology at Fudan University Shanghai Cancer Center, have been published in the prestigious academic journal Molecular Cancer. Urothelial carcinoma, also known as UC, is one of the most common types of urinary system tumors, occurring in the renal pelvis, ureter, and bladder.
"Approximately one-fourth of urothelial carcinoma patients are diagnosed at an advanced stage, making early detection crucial," said Professor Ye Dingwei. He further explained that if urothelial carcinoma is detected early, the five-year survival rate of patients can exceed 90%. However, once the cancer infiltrates the muscle layer or metastasizes, the patient's survival time and quality of life are significantly reduced, with a five-year survival rate of less than 10% for advanced-stage patients.
Currently, the "gold standard" for diagnosing urothelial carcinoma is cystoscopy or ureteroscopy combined with pathological biopsy. However, these invasive procedures have relatively low patient compliance. Existing non-invasive diagnostic methods for urothelial carcinoma based on urine, such as urinary cytology, FISH, and NMP22, have limitations in terms of sensitivity (especially for low-grade tumors and upper urinary tract urothelial carcinoma) and accuracy.
Professor Ye Dingwei emphasized the urgent need for a non-invasive, convenient, and accurate diagnostic tool for urothelial car...
